Shares of Idenix Pharmaceuticals Inc. (NASDAQ: IDIX)
are soaring in trading today after the Cambridge, Massachusetts-based
biopharmaceutical company announced the advancement of its HCV development
pipeline. Idenix’s CEO said that over the past year the company has made
substantial progress in both its core nucleotide and NS5A programs.
Idenix shares rose to a new 52-week high of $10.39
in trading today. At last check, the stock was up more than 34% on above
average volume. The rally has pushed Idenix shares above their 50-day and
200-day moving averages.
To get more information on Idenix Pharmaceuticals
Inc. please click here…
